Company Profile
SkinCure Oncology is a US-based provider of image-guided superficial radiation therapy (IG-SRT) solutions, headquartered in 200 South Frontage Road, Suite 200, Burr Ridge, Illinois 60527, United States. Founded in 2016, the company operates as a private entity backed by H.I.G. Capital, partnering with dermatologists, Mohs surgeons and radiation oncologists to bring cancer center-level care to private practices nationwide. The company employs approximately 550 staff and has supported more than 380 practice partners in treating over 140,000 patients.
Core Products ＆ Technologies
Image-Guided Superficial Radiation Therapy
• GentleCure Experience™: A comprehensive practice partnership model delivering IG-SRT with clinical support, patient education and adaptive radiotherapy protocols
• GentleBeam™: An FDA-cleared image-guided SRT system using Photosonic™ laser-induced acoustic pressure wave imaging for enhanced visualization of skin layers and blood vessels, cleared in March 2026
• Photosonic™ Technology: Proprietary laser-generated imaging enabling precise definition of treatment areas and real-time tumor response assessment
Clinical Support ＆ Services
• Adaptive Radiotherapy Protocols: Image-guided dose adjustment based on high-resolution dermal ultrasound feedback throughout the treatment course
• Practice Integration Services: Comprehensive support including radiation suite design, regulatory compliance, staffing and reimbursement navigation
Market Position ＆ Certifications
SkinCure Oncology holds an industry-leading position in the US image-guided superficial radiation therapy service market, competing with Sensus Healthcare as an alternative non-surgical treatment provider in the dermatology setting. Key strengths include:
• 10+ years of US clinical heritage in non-invasive skin cancer treatment
• Clinical outcomes: 99.3% cure rate with adaptive radiotherapy protocol for appropriately selected non-melanoma skin cancers; 99.8% patient satisfaction rate
• Regulatory compliance: GentleBeam FDA 510(k) cleared; IG-SRT protocols compliant with state radiation protection regulations
• Published evidence: Peer-reviewed publications supporting IG-SRT efficacy and safety
• National scale: 380+ physician partners across the United States
Corporate Timeline
2016 — Founded in Burr Ridge, Illinois based on graduate research into superficial radiotherapy as a Mohs surgery alternative
2024 — H.I.G. Capital acquires SkinCure Oncology Intermediate LLC with senior-secured financing arranged by Marathon Asset Management
2026 — GentleBeam receives FDA 510(k) clearance and enters commercial rollout; dedicated CPT codes for SRT and IG-SRT take effect
Target Markets ＆ Applications
• Non-Melanoma Skin Cancer: IG-SRT for basal cell carcinoma and squamous cell carcinoma in dermatology and oncology practices
• Keloid Management: Post-surgical and standalone radiation therapy for keloid scar prevention and reduction
• Dermatology Practice Enhancement: Comprehensive cancer center model enabling private practices to offer in-office radiation therapy with full clinical and operational support
Contact Information
Global Headquarters
Address: 200 South Frontage Road, Suite 200, Burr Ridge, Illinois 60527, United States
Corporate Online Presence
Website: skincureoncology.com
Patient Information: gentlecure.com
